{"nctId":"NCT01813890","briefTitle":"A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo","startDateStruct":{"date":"2013-01"},"conditions":["Hallux Valgus"],"count":60,"armGroups":[{"label":"Tapentadol IR 50 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tapentadol IR 50 mg"]},{"label":"Tapentadol IR 75 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Tapentadol IR 75 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tapentadol IR 50 mg","otherNames":[]},{"name":"Tapentadol IR 75 mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must be undergoing primary unilateral first metatarsal bunionectomy that includes a distal Chevron osteotomy only, with or without the Akin procedure\n* Patients must be healthy or medically stable on the basis of clinical laboratory tests performed at screening\n* Women must be postmenopausal, surgically sterile, abstinent, or practicing or agree to practice an effective method of birth control and have a negative serum pregnancy test at screening and a negative urine pregnancy test before surgery\n* If a male, must use an approved method of birth control and does not donate sperm from the day of study drug administration until 3 months afterwards\n* Qualifying baseline Pain Intensity must be rated as greater than or equal to 4 on an 11-point (0 to 10) PI NRS, recorded within 30 minutes before randomization, no earlier than 10 hours after the first surgical incision and within 9 hours after termination of the continuous Popliteal Sciatic Block (PSB) infusion Exclusion Criteria: - History of seizure disorder or epilepsy, severe traumatic brain injury, episode(s) of unconsciousness of more than 24 hours duration, malignancy in the past 2 years with the exception of successfully treated basal cell carcinoma\n* Mild or moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm within 1 year of screening\n* Renal insufficiency, impaired hepatic function\n* Use of anticonvulsants, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), neuroleptics, serotonin norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs) or triptans","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sum of Pain Intensity Difference (SPID) Over 48 Hours","description":"Pain Intensity (PI) was assessed on an 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted Sum of PID scores over 48 hours. Total score ranges from -480 (worst) to 480 (best) for SPID48. A higher value of SPID indicates greater pain relief.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":"158.52"},{"groupId":"OG001","value":"168.4","spread":"84.50"},{"groupId":"OG002","value":"194.9","spread":"131.13"}]}]}]},{"type":"SECONDARY","title":"Time to First Rescue Medication Use","description":"Rescue medication was defined as any analgesic medication used for participants discontinued due to lack of efficacy (including those started at time of discontinuation) or analgesic medication used during the double-blind period for completed participants.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"84.50"},{"groupId":"OG001","value":"NA","spread":"131.13"},{"groupId":"OG002","value":"NA","spread":"158.52"}]}]}]},{"type":"SECONDARY","title":"Response Rate for 30 Percent or Greater Reduction in Pain Intensity at 12, 24, 48 and 72 Hours","description":"Response rate was defined as the percentage of participants with a 30 percent or greater reduction in pain intensity from baseline to 12, 24, 48, and 72 hours. Pain intensity was assessed on a 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Participants with no assessment at the given time point, who used an analgesic medication prior to the time point, or who had worse pain intensity at the time point compared to baseline were assigned a percent reduction of 0 percent.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"73.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"73.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":null},{"groupId":"OG001","value":"81.0","spread":null},{"groupId":"OG002","value":"68.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":null},{"groupId":"OG001","value":"81.0","spread":null},{"groupId":"OG002","value":"68.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate for 50 Percent or Greater Reduction in Pain Intensity at 12, 24, 48 and 72 Hours","description":"Response rate was defined as the percentage of participants with a 50 percent or greater reduction in pain intensity from baseline to 12, 24, 48, and 72 hours. Pain intensity was assessed on a 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. Participants with no assessment at the given time point, who used an analgesic medication prior to the time point, or who had worse pain intensity at the time point compared to baseline were assigned a percent reduction of 0 percent.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"42.9","spread":null},{"groupId":"OG002","value":"57.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"61.9","spread":null},{"groupId":"OG002","value":"73.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"76.2","spread":null},{"groupId":"OG002","value":"68.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":null},{"groupId":"OG001","value":"81.0","spread":null},{"groupId":"OG002","value":"68.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Sum of Pain Intensity Differences (SPID) Over 12, 24 and 72 Hours","description":"Pain Intensity (PI) was assessed on an 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted Sum of PID scores over 12, 24, and 72 hours. Total score ranges from -120 (worst) to 120 (best) for SPID12, -240 (worst) to 240 (best) for SPID24, -720 (worst) to 720 (best) for SPID72. A higher value of SPID indicates greater pain relief.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":"32.22"},{"groupId":"OG001","value":"30.3","spread":"17.24"},{"groupId":"OG002","value":"34.7","spread":"25.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"69.37"},{"groupId":"OG001","value":"67.5","spread":"40.90"},{"groupId":"OG002","value":"82.0","spread":"57.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.6","spread":"252.89"},{"groupId":"OG001","value":"281.3","spread":"129.48"},{"groupId":"OG002","value":"316.1","spread":"206.81"}]}]}]},{"type":"SECONDARY","title":"Total Pain Relief (TOTPAR) Over 12, 24, 48, and 72 Hours","description":"Participants rated pain relief on 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Total Pain Relief (TOTPAR) was calculated as the time-weighted sum of pain relief scores up to Hour 12, 24, 48, and 72. Total score ranges from 0 (worst) to 48 (best) for TOTPAR12, 0 (worst) to 96 (best) for TOTPAR24, 0 (worst) to 192 (best) for TOTPAR48, and 0 (worst) to 288 (best) for TOTPAR72. A higher value of TOTPAR indicated greater pain relief.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":"11.29"},{"groupId":"OG001","value":"22.5","spread":"10.27"},{"groupId":"OG002","value":"24.4","spread":"10.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":"24.50"},{"groupId":"OG001","value":"48.2","spread":"22.07"},{"groupId":"OG002","value":"54.1","spread":"20.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.2","spread":"62.26"},{"groupId":"OG001","value":"115.6","spread":"45.06"},{"groupId":"OG002","value":"123.5","spread":"49.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112.6","spread":"103.19"},{"groupId":"OG001","value":"187.3","spread":"68.03"},{"groupId":"OG002","value":"194.1","spread":"74.63"}]}]}]},{"type":"SECONDARY","title":"Sum of Pain Relief and Pain Intensity Differences (SPRID) Over 12, 24, 48, and 72 Hours","description":"Participants rated pain relief on 5-point categorical scale of 0-4 (0=none, 1=A little, 2=Some, 3=A lot, 4=Complete). Pain Intensity (PI) was assessed on an 11-point numerical rating scale from 0=no pain to 10=pain as bad as you can imagine. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. PRID is the sum of pain relief and PID at the same assessment time. SPRID was calculated as the time-weighted Sum of PRID scores over 12, 24, 48, and 72 hours. Total score ranges from -120 (worst) to 168 (best) for SPRID12, -240 (worst) to 336 (best) for SPRID24, -480 (worst) to 672 (best) for SPRID48, and -720 (worst) to 1008 (best) for SPRID72. A higher value of SPRID indicates greater pain relief.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":"41.51"},{"groupId":"OG001","value":"52.8","spread":"25.66"},{"groupId":"OG002","value":"59.1","spread":"33.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":"90.14"},{"groupId":"OG001","value":"115.7","spread":"59.74"},{"groupId":"OG002","value":"136.0","spread":"72.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119.1","spread":"214.14"},{"groupId":"OG001","value":"284.0","spread":"122.07"},{"groupId":"OG002","value":"318.4","spread":"171.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204.3","spread":"346.52"},{"groupId":"OG001","value":"468.6","spread":"185.43"},{"groupId":"OG002","value":"510.2","spread":"268.96"}]}]}]},{"type":"SECONDARY","title":"Patient Global Impression of Change (PGI-C) Score at 72 Hours","description":"The PGI-C is a 7-point scale that requires the participants to assess how much their illness has improved or worsened relative to a baseline state at the beginning of the intervention. The response options are: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; and 7=very much worse. Higher scores indicate worsening.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"71.4","spread":null},{"groupId":"OG002","value":"73.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"14.3","spread":null},{"groupId":"OG002","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"9.5","spread":null},{"groupId":"OG002","value":"10.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"4.8","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"10.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Dizziness","Nausea","Vomiting","Pyrexia","Headache"]}}}